Tesamorelin As the FDA-approved choice for visceral fat reduction, Tesamorelin streamlines abdominal contouring with growth hormone stimulation, akin to premier GHRHs but with refined subtlety
Those chasing strength or fat-loss goals value steady energy over quick spikes
Response timeline varies by individual and depends on baseline metabolic health, lifestyle factors, and adherence to the protocol
Common injection sites include the abdominal area (at least 2 inches from the navel), thighs, or back of the upper arms
The NNMT enzyme it inhibits is constitutively expressed in adipose tissue and liver, meaning timing relative to meals is less critical than consistency
Investors believe its a $1-billion-to-$3-billion-a-year market, but hard figures are elusive, because most peptides are sold on the quasi-legal gray market